AB Science has a unique and diversified portfolio of indications, including several advanced-stage programs.

Filter by compound
6 indications shown
AB Science clinical development pipeline
Platform Drug Therapeutic area Indication Development stage
Tyrosine Kinase Inhibitor Masitinib (oral) Neurodegenerative diseases Amyotrophic Lateral Sclerosis
Phase 3
Tyrosine Kinase Inhibitor Masitinib (oral) Neurodegenerative diseases Progressive Forms of Multiple Sclerosis
Phase 3
Tyrosine Kinase Inhibitor Masitinib (oral) Neurodegenerative diseases Alzheimer’s Disease
Phase 3
Tyrosine Kinase Inhibitor Masitinib (oral) Blood diseases Sickle Cell Disease
Phase 1
Oncology Platform AB8939 (IV) Hematology Acute Myeloid Leukemia (AML)
Phase 1/2
Oncology Platform AB12319 (oral) Oncology Sarcomas, solid tumors
Preclinical

Development programs

Access programs by indication

MasitinibAmyotrophic lateral sclerosisExplore the program →MasitinibProgressive forms of multiple sclerosisExplore the program →MasitinibAlzheimer’s diseaseExplore the program →MasitinibSickle cell diseaseExplore the program →AB8939Acute myeloid leukemiaExplore the program →